1. ALLA AKTIER
  2. NYHETER
  3. XSPRAY PHARMA

Xspray Pharma

Nyheter Xspray Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Xspray Pharma publishes its Annual Report 2025

REG

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today publishes its Annual Report for the financial year 2025.

An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma:
“In 2025, Xspray took several decisive steps on our journey to becoming a commercial pharmaceutical company. While we cannot yet determine the outcome of the ongoing regulatory processes, we do know that we have created the best possible conditions to launch not only our first, but our first two products in the U.S. market during the second half of the year. As Xspray Pharma now transforms into a commercial-stage pharmaceutical company, a new chapter in the company’s history is being written, something both the company and I personally have worked towards for 20 years.”

The annual report is attached, and can also be downloaded from the company's website, www.xspraypharma.com.

For further information, please contact:

Jacob Nyberg, IR
Xspray Pharma AB (publ)
Tel: + 46 (0) 70 767 08 83
E-mail: ir@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development utilizing its innovative, patent protected HyNap™ technology platform to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology market segment, often with high drug prices. The company’s goal is to become the market leader in improved PKI’s for cancer treatment. Xspray Pharma’s lead drug candidate, Dasynoc® and XS003-nilotinib (an optimized version of Tasigna®) are currently undergoing FDA review. Dasynoc is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose due to a better solubility profile. Its compatibility with proton pump inhibitors (PPIs), which are often co-prescribed to patients with CML and ALL, is a significant advantage. Xspray Pharma is building a robust product portfolio, including XS003-nilotinib and XS008-axitinib (an optimized version of Inlyta®) and XS025-cabozantinib (an optimized version of Cabometyx®).

The Xspray Pharma AB-share is trading at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com.

This information is information that Xspray Pharma AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-26 08:00 CET.

Attachments

20260326 Xspray Pharma Annual Report 2025 Eng
549300NGRQCNZ3X4L157-2025-12-31-sv

Datum 2026-03-26, kl 08:00
Källa MFN
Bifogade filer
20260326 Xspray Pharma Annual Report 2025 Eng
549300NGRQCNZ3X4L157-2025-12-31-sv